59,165 Shares in Immunome, Inc. (NASDAQ:IMNM) Purchased by Emfo LLC

Emfo LLC bought a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 59,165 shares of the company's stock, valued at approximately $633,000. Emfo LLC owned about 0.14% of Immunome at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Point72 Asset Management L.P. bought a new stake in Immunome in the second quarter valued at about $3,307,000. TD Asset Management Inc acquired a new stake in shares of Immunome in the 3rd quarter valued at $1,063,000. Cerity Partners LLC acquired a new stake in shares of Immunome during the 4th quarter worth about $656,000. The Manufacturers Life Insurance Company bought a new position in Immunome during the 3rd quarter valued at about $449,000. Finally, Acadian Asset Management LLC bought a new position in Immunome during the 3rd quarter valued at about $414,000. 44.58% of the stock is owned by institutional investors.

Immunome Trading Down 8.4 %

Shares of Immunome stock traded down $1.73 during midday trading on Monday, reaching $18.85. The company had a trading volume of 718,468 shares, compared to its average volume of 690,748. The stock has a fifty day simple moving average of $23.40 and a 200 day simple moving average of $14.71. Immunome, Inc. has a 1-year low of $4.44 and a 1-year high of $30.96. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.50 and a beta of 1.66.

Wall Street Analyst Weigh In

Several analysts have weighed in on IMNM shares. Leerink Partnrs reaffirmed an "outperform" rating on shares of Immunome in a research note on Monday, January 29th. SVB Leerink initiated coverage on Immunome in a report on Monday, January 29th. They set an "outperform" rating and a $30.00 price target for the company. Guggenheim started coverage on Immunome in a research report on Monday. They issued a "buy" rating and a $35.00 price objective for the company. Finally, Wedbush increased their target price on Immunome from $27.00 to $33.00 and gave the stock an "outperform" rating in a report on Monday, April 1st. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $32.67.

Immunome Company Profile

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.